OTS186935 is primarily utilized in the field of oncology research due to its potential as a therapeutic agent. It is being investigated for its ability to target specific pathways involved in cancer cell proliferation and survival. Researchers are exploring its efficacy in inhibiting tumor growth, particularly in cases where conventional treatments have shown limited success. Additionally, OTS186935 is being studied for its role in enhancing the effectiveness of other cancer therapies, such as chemotherapy and immunotherapy, by sensitizing cancer cells to these treatments. Its application extends to preclinical studies aimed at understanding its mechanism of action and identifying potential biomarkers for patient selection in clinical trials.